Tech Transfer eNews Blog
Industry-Sponsored Research Management sample issue

Cedars-Sinai launches initiative to develop treatments for microbiome disorders


By Jesse Schwartz
Published: June 27th, 2018

Cedars-Sinai has launched an initiative to speed the development or drugs and healthcare devices that treat patients with gastrointestinal and metabolic diseases caused by disorders of the microbiome.

The healthcare organization has formed a team of physician-scientists and others in its Medically Associated Science and Technology (MAST) program, who together will focus on developing solutions for disorders of the microbiome, an ecosystem of single-cell organisms that protect the human gut from infection. The microbiome can also disrupt healthy gastrointestinal function, resulting in diarrhea, constipation and other ailments.

The MAST investigators will focus initially on irritable bowel syndrome and small intestinal bacteria overgrowth caused by microbiome disorder. The initiative is supported by the Cedars-Sinai Technology Transfer Office in partnership with the Burns & Allen Research Institute.

“Discoveries best happen at the bedside of patients by doctors who are invested in their care,” says Mark Pimentel, associate professor at Cedars-Sinai and executive director of MAST. “We have found that many of our discoveries have benefitted a vast number of patients here and around the world. We expect that, with the formation of the MAST program, we will be able to help millions more with our growing pipeline of novel diagnostics and therapeutics.”

In addition to their scientific expertise, the MAST team has a track record of successfully navigating the intensive process of seeking and achieving FDA approval.

“Through MAST, we are accelerating the development of innovations that will lead to faster diagnostics and treatments for patients,” says Ruchi Mathur, associate professor at Cedars-Sinai and director of clinical research at MAST. “Our team is dedicated to improving the lives of patients who are affected by gastrointestinal and metabolic diseases.”

Source: Newswise

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment